Kalbe Farma KLBF IJ -Buy- Transforming the brand
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Consumer Durables SH JW SC 1.9K 12th Jun, 2025
Capturing in-home consumption trend
As noted in our previous report (1Q25 review — Shifting to in-home consumption), we observed that middle-income consumers are moving to in-home consumption activities in order to save money. This situation creates higher demand for frozen/chilled processed meat products (Fig. 1), given the good taste and practicality to cook at home; those products are also cheaper than fresh chicken/beef as frozen food can be stored and shared for long. We estimate that CMRY, through its Kanzler brand, can capture the trend, resulting in very strong +31% y-y sales growth for Kanzler in 1Q25 (vs. +13% y-y estimated by the industry); the double-digit sales growth momentum should resume in 2Q25F, in our view. We note that Kanzler now has a more complete product range with its recent launches of affordable packs priced at IDR5,000, which we think is a perfect timing to capture the middle-income-class’ downtrading trend. On top of that, CMRY is equipped with around 7K Miss Cimory agents who can go door-to-door to customers’ houses, catering to in-home consumption activities.
Dairy sales start to recover
We expect CMRY’s dairy sales to slightly rebound in 2Q25F, with positive y-y growth (vs. -11% y-y in 1Q25), which is partly driven by a slowdown in the market leader’s (Ultrajaya [ULTJ IJ, Buy]) promotions roll-out. However, given the middle-income downtrading trend and lesser out-of-home spending (i.e., ready-to-drink beverages), we estimate that CMRY’s overall dairy sales growth this year should only reach low-single-digit growth y-y. Most of the growth will be driven by volume, especially on the back of market share gains in 2Q25F onwards amid the industry slowdown.
Sales channels continue to expand
In our view, general trade (GT) would be the main growth channel for CMRY this year on the back of: 1) additional new point of sales – the company can easily reach 200K stores by FY25F (vs. 167K in 4Q24 and 178K in 1Q25); 2) more affordable products are mostly launched in GT, which is suitable for the current middle-income class downtrading trend; and 3) more government stimulus to lower-tier cities and rural areas makes GT a more relevant channel to benefit due to proximity advantages. Domestically, CMRY still has plenty of room to grow outside Java, especially in encouraging areas like Sulawesi Island which has one of the fastest growing GDP growth in a decade. The company has also slowly expanded its business in the Philippines, which currently still contributes ~1% of sales; management views that its yogurt products have received strong acceptance in this region. Lastly, we believe that the Miss Cimory channel should do well this year, backed by the in-home consumption trend, not to mention the higher productivity given the more new SKUs.
Margin risks should be manageable
We estimate 2Q25F gross profit margin (GPM) to be similar to the 1Q25 level, though we might start to see a lower GPM in 3Q25F due to higher USD costs and more expensive powder milk prices. However, we think overall EBIT margin will likely be stable as management can adjust its A&P spending to compensate for the lower GPM. All in all, we do not see any major risks to CMRY’s profitability for this year.
Maintain Buy
In our view, it would be impressive if CMRY maintains its double-digit earnings growth amid the economic slowdown. We forecast CMRY’s NPAT could still grow +17% y-y in FY25F. We reaffirm our Buy rating and TP of IDR6,700, using a FY25F target P/E of 30x. Currently, the stock is trading at 21.4x FY25F P/E (EPS: IDR224), which is justified by its consistent double-digit growth and feasibility even amid the economic slowdown. Downside risks: higher-than-expected USD costs.
INVESTMENT RATINGS
A rating of ‘Buy’, indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of ‘Neutral’, indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of ‘Reduce’, indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of ‘Suspended’, indicates that the rating, target price, and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies. Securities and/or companies that are labelled as ‘Not Rated’ or ‘No Rating’ are not in regular research coverage. Benchmark is Indonesia Composite Index (‘IDX Composite’). A ‘Target Price’, if discussed, indicates the analyst’s forecast for the share price with a 12-month time horizon, reflecting in part of the analyst’s estimates for the company’s earnings, and may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market in general.
GENERAL DISCLOSURE/DISCLAIMER
This report is prepared by PT Verdhana Sekuritas Indonesia (“PTVSI”) a securities company registered in Indonesia, supervised by Indonesia Financial Services Authority (OJK) and a member of the Indonesia Stock Exchange (IDX).
This report is intended for client of PTVSI only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of PTVSI.
The research set out in this report is based on information obtained from sources believed to be reliable, but PTVSI do not make any representation or warranty as to its accuracy, completeness or correctness. The information in this report is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the company (or companies) referred to in this report. Any information, valuations, opinions, estimates, forecasts, ratings or targets herein constitutes a judgment as of the date of this report is published, and there is no assurance that future results or events will be consistent.
This report is not to be construed as an offer or a solicitation of an offer to buy or sell any securities or financial products. PTVSI and its associates, its directors, and/or its employees may from time to time have interests in the securities mentioned in this report or it may or will engage in any securities transaction or other capital market services for the company (companies) mentioned herein.
ANALYST CERTIFICATION
The research analyst primarily responsible for the content of this report and certifies that the views about the companies including their securities expressed in this report accurately reflect his/her personal views. The analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.
RESTRICTIONS ON DISTRIBUTION
By accepting this report, the recipient hereof represents and warrants that you are entitled to receive such report in accordance with the restrictions and agrees to be bound by the limitations contained herein. Neither this report nor any copy hereof may be distributed except in compliance with applicable Indonesian capital market laws and regulations.
| Rating Remains | Buy |
| Target price Remains | IDR 6,700 |
| Closing price 10 June 2025 | IDR 4,800 |
Sandy Ham (sandy.ham@verdhana.id)
Jody Wijaya (jody.wijaya@verdhana.id)
Samuel Christian (samuel.christian@verdhana.id)
saya
Consumer health is a very crucial division for KLBF, as it possesses the highest margin,
Based on our survey of distributors and wholesalers, MYOR's domestic sales may have grown
As mentioned in our previous reports, Indonesia local FMCG companies have
Our analysis of FMCG and retail sales data of companies we track across Indonesia suggests that Sulawesi,
AMRT has consistently outperformed its FMCG peers in terms of sales growth over the past decade
Indonesia is a young nation (110mn population are below 40yrs, based on BPS) as well as social media-savvy (th